Overview
| |||||||||||||||||||||||||||||||||||||||||||||
Alphabetical Reference of Nutritional Support | |
Formula Catch Phrase |
Key Benefits |
Alpha Lipoic Acid for Antioxidant Support |
Alpha-lipoic acid (ALA) is an important intracellular antioxidant for the management and prevention of diabetes and diabetic complications, such as neuropathy, nephropathy and cardiovascular disease. ALA regenerates glutathione and supports mitochondrial energy production, whilst improving insulin sensitivity and heavy metal clearance. |
Enhanced Bioavailability Ubiquinol for Energy and Cardiovascular Health |
Ubiquinol is the active form of coenzyme Q10, a potent antioxidant and mitochondrial stimulant. Efficient conversion of inactive ubiquinone to ubiquinol is reported to decrease with aging and in conditions with high oxidative stress, thus making active ubiquinol best suited for patients whose ability to convert is compromised. |
High Bioavailability Zinc with Vitamin C |
Zinc and vitamin C are amongst the most critical nutrients for healthy immunity and skin, involved in wound healing, and resistance to infection. |
Highly Bioavailable Palmitoylethanolamide (PEA) With Endocannabinoid Action |
PEA is a bioactive lipid that directly modulates endocannabinoid signalling, indirectly increasing cannabinoid receptor activity throughout the nervous system, including microglial cells and astrocytes, as well as receptor activity in immune cells. PEA’s actions enhance anti-neuroinflammatory, analgesic and neuroprotective pathways, benefiting chronic pain, including neuropathic pain, in addition to neurodegenerative conditions. |
|
High Potency Taurine, Glycine and Magnesium for Cardiovascular Health
|
Magnesium is essential to vascular health to prevent endothelial changes and atherosclerosis. Low magnesium is pro-thrombotic and promotes advanced plaque rupture and acute cardiovascular events. Cholesterol synthesis is regulated by magnesium-dependant enzymes, and magnesium deficiency is associated with cholesterol and triglyceride dyslipidaemia. Magnesium has been compared favourably to statin therapy for lowering cholesterol. Important enzymes involved in the conversion and activity of vitamin D are also magnesium dependant, therefore magnesium supplementation may be required for vitamin D activity and restoration. |
Indian Barberry and Milk Thistle for Blood Glucose Metabolism and Liver Function Support |
In obese type 2 diabetics, excess energy stored within visceral organs promotes insulin resistance, leading to elevations in blood glucose and cholesterol. A blend of berberine, milk thistle and chromium in combination with diet and lifestyle support can help rebalance these patterns of metabolic dysfunction. |
Mixed Tocopherols & Tocotrienols for Free Radical Defence |
A mixed-form vitamin E supplement of the highest potency, including all 8 isoforms of vitamin E for broadest range of activity with cardio-protective benefits. Shown to reduce cholesterol synthesis and LDL oxidation, reduce ApoB, increase ApoA1, as well as being antithrombotic and anti-inflammatory. Safe for long term cardiovascular protection. |
Phytonutrients for Eye Health |
Clinically trialled blackcurrant and marigold extracts, plus nutrients help to reduce eye strain and reduce the risk of age related eye disease. |
Resveratrol Age Well |
Resveratrol and quercetin activate sirtuins to increase cellular defence status and enhance neuronal and cellular survival. Also shown to regulate post-prandial lipaemia and inflammation, this antioxidant combination supports cardiovascular system, immune function and normal blood sugar levels due to supporting cellular resilience and insulin sensitivity. |
Specialised Pro-Resolving Mediators |
SPMs are lipid mediators that promote resolution, reduce pain, encourage clearance of pathogens and mitigate pathological inflammation, without immunosuppression. SPMs regulate macrophage polarisation; triggering the switch from M1 (proinflammatory) to the M2 (anti-inflammatory) phenotype, therefore promoting resolution. |
Vitamin D3 Capsules or Liquid |
Suboptimal vitamin D intake &/or sun exposure is associated with increased risk of developing insulin resistance with increased risk of infection and cardiovascular disease. Supplementation supports healthy vitamin D levels. |
Supportive Lifestyle Programs | |
Shake It Practitioner Weight Management Program |
There is growing evidence that obesity is a disorder of energy homeostasis, and that the set-point for obese individuals is set to a higher level. The Shake It Practitioner Weight Management Program is a novel 3 phase program structure to prevent metabolic adaptation, reset the patient’s metabolic set point, and provide regular psychological breaks from active dieting in order to achieve sustained weight loss. The program as collection of supportive materials in order to implement behaviour change techniques and two diet options: Ketogenic (low carbohydrate, higher fat), or Low fat (lower fat, liberal carbohydrate). For Metabolic syndrome patient’s carbohydrate-restricted ketogenic diet is the diet with the most supporting evidence for those with insulin resistance. Reducing dietary glycaemic load will reduce insulin release and help patients lose fat, particularly visceral adipose tissue, thus helping to minimise the risk of many chronic illnesses. |
Wellness and Healthy Ageing Program |
This program recommends a low glycaemic load diet with lifestyle recommendations for exercise, relaxation, intellectual stimulation and effective stress management – all factors associated with healthy ageing and chronic disease prevention. |
Metagenics Clinical Detoxification Program |
Dysbiosis and gut-derived inflammation, as well as environmental toxicity (persistent organic pollutants) are all recognised drivers of insulin resistance and metabolic inflexibility. The Metagenics Clinical Detoxification Programs are designed to address the primary source of toxicity in patients, and encourage elimination of and protection against these toxins. A questionnaire is available for patients to complete which assist the Practitioner in determining the most appropriate program. There are three programs available:
|
Definition
Type 2 diabetes mellitus was once called adult-onset diabetes, typically affecting individuals older than 40 years. Now, because the epidemic of obesity and inactivity in children, type 2 diabetes is occurring at younger and younger ages: it has been diagnosed in children as young as 2 years of age who have a family history of diabetes. Type 2 diabetes is characterised by peripheral insulin resistance with an insulin-secretory defect that varies in severity.
For type 2 diabetes to develop, insulin resistance and delayed insulin production from the pancreas occurs. All overweight individuals have some degree of peripheral insulin resistance, but diabetes develops after the progression from normal glucose tolerance to abnormal glucose tolerance. Postprandial glucose levels gradually damage the beta cells of the pancreas. A powerful fore-runner to the type 2 diabetes is evidence of early pancreatic beta cell damage in reactive hypoglycaemia (for more information, please refer to Hypoglycaemia protocol). Reactive hypoglycaemia occurs as excessive fatty acids and glucose damage insulin secreting beta-cells and cause early-phase insulin release failure after eating. Despite having elevated blood sugars, the patient feels tired and hungry immediately after eating. This is followed by an over-compensation of late-phase insulin production, which causes a true hypoglycaemia, causing powerful hunger and fatigue, to continue the cycle.
If patients with reactive hypoglycaemia and insulin resistance remain untreated with dietary and lifestyle intervention, they will commonly progress to more severe pancreatic dysfunction and diabetes. These patients tend to exhibit the signs and symptoms of hypoglycaemia (low blood sugar), despite having elevated blood sugars of 4.5 to 6.0, or even above. Progression to more severe metabolic dysfunction and diabetes, the profound lack of energy occurs due to a blockade in mitochondrial energy production induced by excessive energy consumption, with elevated free fatty acids and hyperglycaemia, rather than lack of glucose.
Unfortunately, this lack of cellular energy production creates a strong unconscious drive to seek out energy dense foods and to conserve energy (to be sedentary) in an attempt to increase cellular energy, despite having a conscious desire to lose weight and get fitter.
Approximately 90 percent of patients who develop type 2 diabetes are obese. Because patients with type 2 diabetes retain some ability to secrete endogenous insulin, those who are taking insulin do not develop diabetic ketoacidosis (DKA) if they stop taking it for some reason. Therefore, they are considered to require insulin but not to depend on insulin. Moreover, patients with type 2 diabetes often do not need treatment with oral anti-diabetic medication or insulin if they lose weight.
Aetiology and Risk factors |
|
Major causative factors and risk factors that can contribute to the incidence of metabolic dysfunction include the following:
|
Pathology Tests | ||
Insulin Resistance and Blood Sugar Management | ||
Fasting glucose |
Normal reference range: At risk (monitor): Diabetes: |
3.9 - 5.5 mmol/L 5.5 - 6.9 mmol/L > 7.0mmol/L |
Fasting insulin |
Normal reference range: At risk (monitor): Diabetes: |
4 - 9 mU/L mmol/L 10 - 14 mU/L (mild I.R.) 14 mU/L (mod to severe I.R.) |
|
Homeostasis Model Assessment Index of insulin resistance (HOMA-IR) |
A refinement of fasting serum insulin; HOMA-IR Index = [mean of three fasting insulin (mU/L)] x fasting glucose (mmol/L) divided by 22.5. |
|
|
Normal reference range: At risk (monitor): Diabetes: |
< 2.0 2.0 – 2.2 2.2 – 3.0 (mod to severe) >3.0 (severe) |
|
Glucose tolerance test (GTT) – plasma values two hours after 75 g glucose load |
Normal reference range: At risk (monitor): Diabetes: |
<7.9 mmol/L 7.9 – 11.0 mmol/L >11.0 mmol/L |
HbA1c |
Normal reference range: At risk (monitor): Diabetes: |
4 – 5.6% 5.7 – 6.4 % > 6.5% |
TESTING |
INTERPRETATION GUIDELINES |
|
Homocysteine |
Raised serum levels of this amino acid have been associated with increased risk of coronary artery disease and stroke, particularly in patients with dyslipidaemia. Ideally, homocysteine levels should be less than 10 nmol/L. |
|
C-Reactive Protein (hsCRP) |
Indicator of inflammatory processes. Normal range is 0.2–3mg/L, but ideally levels should be < 1mg/L. |
|
Liver Function Test (LFT) |
This is a blood test that measures serum levels of any of several liver enzymes. An elevated liver function test is a sign of possible liver damage. Normal Values: Albumin: 32-45g/L Total bilirubin: <20mmol/L AP (Alkaline Phosphatase): 25-100U/L |
|
Footnote
Formulations containing Palmitoylethanolamide (PEA) are not to be used for more than 21 consecutive days and may interact with other prescription analgesic medicines.